Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.

As a basis for predicting structural features that may lead to the design of more potent and selective inhibitors of choline acetyltransferase (ChAT), the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies were carried out on a series of trans-1-methyl-4-(1-naphthylvinyl)pyridinium (MNVP+) analogs, which are known ChAT inhibitors. 3D-QSAR studies were carried out using the comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) methods. Since these inhibitors have extremely shallow potential energy minimum energy wells and low barriers to rotation, two dihedral angles unique to these inhibitors were systematically modified to reflect the energetically preferred conformations as determined by force field calculations. An optimum alignment rule was devised based on the conformations obtained from the molecular mechanics studies, using a common substructure alignment method. The studies involve a set of 21 compounds and experimentally determined molar IC50 values were used as the dependent variable in the analysis. The 3D-QSAR models have conventional r2-values of 0.953 and 0.954 for CoMFA and CoMSIA, respectively; similarly, cross-validated coefficient q2-values of 0.755 and 0.834 for CoMFA and CoMSIA, respectively, were obtained. On the basis of these predictive r2-values the model was tested using previously determined IC50 values. CoMSIA 3D-QSAR yielded better results than CoMFA.

A computational modeling and molecular dynamics study of the Michaelis complex of human protein Z-dependent protease inhibitor (ZPI) and factor Xa (FXa).

Protein Z-dependent protease inhibitor (ZPI) and antithrombin III (AT3) are members of the serpin superfamily of protease inhibitors that inhibit factor Xa (FXa) and other proteases in the coagulation pathway. While experimental structural information is available for the interaction of AT3 with FXa, at present there is no structural data regarding the interaction of ZPI with FXa, and the precise role of this interaction in the blood coagulation pathway is poorly understood. In an effort to gain a structural understanding of this system, we have built a solvent equilibrated three-dimensional structural model of the Michaelis complex of human ZPI/FXa using homology modeling, protein-protein docking and molecular dynamics simulation methods. Preliminary analysis of interactions at the complex interface from our simulations suggests that the interactions of the reactive center loop (RCL) and the exosite surface of ZPI with FXa are similar to those observed from X-ray crystal structure-based simulations of AT3/FXa. However, detailed comparison of our modeled structure of ZPI/FXa with that of AT3/FXa points to differences in interaction specificity at the reactive center and in the stability of the inhibitory complex, due to the presence of a tyrosine residue at the P1 position in ZPI, instead of the P1 arginine residue in AT3. The modeled structure also shows specific structural differences between AT3 and ZPI in the heparin-binding and flexible N-terminal tail regions. Our structural model of ZPI/FXa is also compatible with available experimental information regarding the importance for the inhibitory action of certain basic residues in FXa.